Korsana Biosciences announced a $175 million financing to accelerate its preclinical Alzheimer’s program built on a platform that shuttles antibodies across the blood–brain barrier. The company said the funding will support preclinical development and IND‑enabling work for brain‑penetrant therapeutic antibodies. Korsana’s approach joins other industry efforts—Roche and AbbVie have clinical‑stage programs using similar BBB‑crossing concepts—positioning the startup in a crowded but strategically important area of neurodegenerative drug development. Investors backing Korsana signaled sustained appetite for platform plays that address delivery barriers in CNS disease, a central bottleneck for many neurotherapeutic programs.